Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-12-21
2009-12-22
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S281000, C544S280000, C544S256000, C514S259300, C514S259310
Reexamination Certificate
active
07635699
ABSTRACT:
Compounds are provided having the formula (I)wherein X for each occurrence is N or C-A, and R, Y, A and n are as defined herein, which compounds are dipeptidyl peptidase IV inhibitors and as such are useful in treating diabetes and micro- and macrovascular complications of diabetes, such as retinopathy, neuropathy, and nephropathy.A method for treating diabetes and related diseases employing the above compounds is also provided.
REFERENCES:
patent: 3674836 (1972-07-01), Creger
patent: 3983140 (1976-09-01), Endo et al.
patent: 4027009 (1977-05-01), Grier et al.
patent: 4231938 (1980-11-01), Monaghan et al.
patent: 4346227 (1982-08-01), Terahara et al.
patent: 4448784 (1984-05-01), Glamkowski et al.
patent: 4450171 (1984-05-01), Hoffman et al.
patent: 4499289 (1985-02-01), Baran et al.
patent: 4613610 (1986-09-01), Wareing
patent: 4647576 (1987-03-01), Hoefle et al.
patent: 4681893 (1987-07-01), Roth
patent: 4686237 (1987-08-01), Anderson
patent: 4759923 (1988-07-01), Buntin et al.
patent: 4871721 (1989-10-01), Biller
patent: 4924024 (1990-05-01), Biller
patent: 5006530 (1991-04-01), Angerbauer et al.
patent: 5011930 (1991-04-01), Fujikawa et al.
patent: 5177080 (1993-01-01), Angerbauer et al.
patent: 5260440 (1993-11-01), Hirai et al.
patent: 5273995 (1993-12-01), Roth
patent: 5346701 (1994-09-01), Heiber et al.
patent: 5354772 (1994-10-01), Kathawala
patent: 5385929 (1995-01-01), Bjorge et al.
patent: 5488064 (1996-01-01), Sher
patent: 5491134 (1996-02-01), Sher et al.
patent: 5506219 (1996-04-01), Robl
patent: 5541204 (1996-07-01), Sher et al.
patent: 5594016 (1997-01-01), Ueno et al.
patent: 5595872 (1997-01-01), Wetterau, II et al.
patent: 5612359 (1997-03-01), Murugesan
patent: 5614492 (1997-03-01), Habener
patent: 5631224 (1997-05-01), Efendic et al.
patent: 5686104 (1997-11-01), Mills et al.
patent: 5691322 (1997-11-01), Robl
patent: 5712279 (1998-01-01), Biller et al.
patent: 5712396 (1998-01-01), Magnin et al.
patent: 5739135 (1998-04-01), Biller et al.
patent: 5753675 (1998-05-01), Wattanasin
patent: 5760246 (1998-06-01), Biller et al.
patent: 5770615 (1998-06-01), Cheng et al.
patent: 5776983 (1998-07-01), Washburn et al.
patent: 5827875 (1998-10-01), Dickson, Jr. et al.
patent: 5885983 (1999-03-01), Biller et al.
patent: 5962440 (1999-10-01), Sulsky
patent: 6395767 (2002-05-01), Robl et al.
patent: 6548529 (2003-04-01), Robl et al.
patent: 6653314 (2003-11-01), Cheng et al.
patent: 6995183 (2006-02-01), Hamann et al.
patent: 102 56 264 (2004-06-01), None
patent: 0 142 146 (1984-11-01), None
patent: 0 221 025 (1986-10-01), None
patent: 2 596 393 (1986-05-01), None
patent: 2 205 837 (1988-12-01), None
patent: WO86/03488 (1986-06-01), None
patent: WO86/07054 (1986-12-01), None
patent: WO96/38144 (1996-12-01), None
patent: WO97/12613 (1997-04-01), None
patent: WO97/12615 (1997-04-01), None
patent: WO97/21993 (1997-06-01), None
patent: WO99/00353 (1999-01-01), None
patent: WO99/38501 (1999-08-01), None
patent: WO99/46272 (1999-09-01), None
patent: WO99/61431 (1999-12-01), None
patent: WO99/67278 (1999-12-01), None
patent: WO99/67279 (1999-12-01), None
patent: WO00/01389 (2000-01-01), None
patent: WO01/21602 (2001-03-01), None
patent: WO01/68603 (2001-09-01), None
patent: WO03/033671 (2003-04-01), None
patent: WO 2004/043940 (2004-05-01), None
Dipeptidyl peptidase IV (DPP-IV) inhibitors for type 2 diabetes mellitus; 2007; http://limaye.ecri.org/summary/detail.aspx?doc—id=10028.
Attaby, et. al., Archives of Pharmacal Research (1997), 20(4), 330-337.
Borisy, et. al., Proceedings of the National Academy of Sciences of the United States of America, 100(13) 7977-7982.
Ashworth, D. et al., “4-Cyanothiazolidides as very potent, stable inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chem. Letters, vol. 6(22), pp. 2745-2748 (1996).
Ashworth, D. et al., “2-Cyanopyrrolidides as potent, stable inhibitors of Dipeptidyl Peptidase IV”, Bioorganic & Medicinal Chem. Letters, vol. 6(10), pp. 1163-1166 (1996).
Biller, S. et al., “Isoprenoid (Phosphinylmethyl) phosphonates as Inhibitors of Squalene Synthetase”, J. Medicinal Chemistry, vol. 31(10), pp. 1869-1871 (1988).
Biller, S. et al., “Squalene Synthase Inhibitors”, Current Pharmaceutical Design, vol. 2, pp. 1-40 (1996).
Corey, E.J. et al., “Application of Unreactive Analogs of Terpenoid Pyrophosphates to Studies of Multistep Biosynthesis. Demonstration that “Presqualene Pyrophosphate” Is an Essential Intermediate on the Path to Squalene”, J. Amer. Chem. Soc., vol. 98(5) pp. 1291-1293 (1976).
Cornicelli, J.A. et al., “15-Lipoxygenase and Its Inhibition: A Novel Therapeutic Target for Vascular Disease”, Current Pharmaceutical Design, vol. 5, pp. 11-20 (1999).
Hart, D. et al., “Preparation of Primary Amines and 2-Azetidinones viaN-Trimethylsiyl Imines”, J. Org. Chem., vol. 48(3), pp. 289-294 (1983).
Ghiselli, G., “The Pharmacological Profile of FCE 27677: A Novel ACAT Inhibitor with Potent Hypolipidemic Activity Mediated by Selective Suppression of the Hepatic Secretion of ApoB-100-Containing Lipoprotein”, Cardiovascular Design Reviews, vol. 16(1), pp. 16-30 (1998).
Hara, S., “Ileal Na+/bile acid cotransporter inhibitors”, Drugs of the Future, vol. 24(4), pp. 425-430 (1999).
Johannsson. G. et al., “Growth Hormone Treatment of Abdominally Obese Men Reduces Abdominal Fat Mass, Improves Glucose and Lipoprotein Metabolism, and Reduces Diastolic Blood Pressure*”, J. of Clin. Endocrinology and Metabolism, vol. 82(3), pp. 727-734 (1997).
Krause, B. et al., “ACAT Inhibitors: Physiologic mechanisms for Hypolipidemic and Anti-Atherosclerotic Activities in Experimental Animals”, Inflammation: Mediators and Pathways, pp. 173-198 (1995).
McClard, R. et al., “Novel Phosphonylphosphinyl (P-C-P-C-) Analogues of Biochemically Interesting Diphosphates. Syntheses and Properties of P-C-P-C- Analogues of Isopentenyl Diphosphate and Dimethylallyl Diphosphate”, J. Am. Chem. Soc., vol. 109, pp. 5544-5545 (1987).
Murakami, K. et al., “A Novel Insulin Sensitizer Acts as a Coligand for Peroxisome Proliferator-Activated Receptor-α (PPAR-α) and PPAR-γ”, Diabetes, vol. 47, pp. 1841-1847 (1998).
Nicolosi, R. et al., “The ACAT inhibitor, CI-1011 is effective in the prevention and regression of aortic fatty streak area in hamsters”, Atherosclerosis, vol. 137, pp. 77-85 (1998).
Ortiz de Montellano, P. et al., “Inhibition of Squalene Synthetase by Farnesyl Pyrophosphate Analogues1”, J. of Medicinal Chemistry, vol. 20(2), pp. 243-249 (1977).
Rosenblum, S. et al., “Discovery of 1-(4-Flurophenyl)-(3R)-[3-(4-flurophenyl)-(3S)-hydrozypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): A Designed, Potent, Orally Active Inhibitor of Cholesterol Absorption”, J. Med. Chem., vol. 41, pp. 973-980 (1998).
Salisbury, B. et al., “Hypocholesterolemic activity of a novel inhibitor of cholesterol absorption, SCH 48461”, Atherosclerosis, vol. 115, pp. 45-63 (1995).
Sendobry, S. et al., “Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties”, British J. of Pharmacology, vol. 120, pp. 1199-1206 (1997).
Sliskovic, D. et al., “ACAT Inhibitors: Potential Anti-atherosclerotic Agents”, Current Medicinal Chemistry, vol. 1, pp. 204-225 (1994).
Smith, C. et al., “RP 73163: A Bioavailable Alkylsulphinyl-Diphenylimidazole ACAT Inhibitor”, Bioorganic & Medicinal Chemistry Letters, vol. 6(1), pp. 47-50 (1996).
Sorbera, L. et al., “Treatment of Lipoprotein Disorders ACAT Inhibitor”, Drugs of the Future, vol. 24(1), pp. 9-15 (1999).
Yamada, M. et al., “A Potent Dipeptide Inhibitor of Depeptidyl Peptidase IV”, Bioorganic & Medicinal Chemistry Letters, vol. 8, pp. 1537-1540 (1998).
Morrison J. et al., “The Behavior and Significan
Brigance Robert
Hamann Lawrence G.
Meng Wei
Bristol--Myers Squibb Company
Gibbons Maureen S.
Murray Jeffrey H
Wilson James O
LandOfFree
Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4100741